Edwards(US:EW) Xin Lang Cai Jing·2025-11-07 03:17Core Viewpoint - Edwards Lifesciences continues to showcase its commitment to the structural heart disease field by participating in the China International Import Expo for the sixth consecutive year, highlighting its innovative products and treatment solutions [1] Group 1: Product Launch and Innovation - Edwards Lifesciences presented the PASCAL Precision transcatheter valve repair system, marking its debut at the expo following its launch in Hong Kong [1] - The PASCAL Precision system offers a minimally invasive and reliable intervention option for high-risk surgical patients with mitral and tricuspid regurgitation, with expectations for approval in mainland China next year [1] Group 2: Strategic Partnerships - Edwards has upgraded its strategic collaborations with key industry partners such as Sinopharm Group and Shanghai Pharmaceuticals, aiming to enhance the introduction of advanced technologies and clinical transformation [1] - Wayne Markowitz, Global Vice President for Japan and Asia Pacific, emphasized the company's patient-first philosophy and the importance of the expo as a platform for collaboration [1] Group 3: Market Expansion - The participation in the expo signifies Edwards' efforts to accelerate the extension of its innovative achievements in transcatheter valve repair to the Chinese market [1] - The company aims to leverage the expo as an open window for accelerating the introduction of cutting-edge technologies [1]